Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd announced it has completed its 90-day oral toxicity study of AME-1, its Amanita Muscaria extract.
The psychedelic firm’s research partner KGK Science is now completing the 28-day recovery period and will do a tissue histopathology examination before a final report, which is expected by mid-January 2022.
Toronto-based Psyched is developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
READ: Psyched Wellness presents Amanita muscaria extract AME-1 to Health Canada in pre-submission meeting
The study looked at the effects of Amanita Muscaria on rodents.
In a statement, Psyched said that the new data will provide information on the major toxic effects and indicate target organs and the possibility of accumulation of test chemical. It can also provide an estimate of a no-observed-adverse-effect level of exposure, which can be used in selecting dose levels for chronic studies and for establishing safety criteria for human exposure, according to the company.
"The completion of the 90-day oral toxicity study is a major milestone for Psyched as it provides critical scientific data for the determination of safe dosage levels of AME-1, from which all of our consumer products will be derived as we prepare to launch them to market next year," said Jeffrey Stevens, CEO of Psyched.
"Although we are waiting for the final report, we are pleased to share that there was no mortality or morbidity of any of the test rodents during the study and we look forward to providing the full toxicology and histopathology reports early next year."
Contact Angela at angela@proactiveinvestors.com
Follow her on Twitter @AHarmantas